Holen Sie sich die Stockscreener-App
195.61
1.53%
-3.03
Vorhandelsmarkt:
197.20
1.59
+0.81%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$198.64
Offen:
$199.69
24-Stunden-Volumen:
1.11M
Relative Volume:
0.97
Marktkapitalisierung:
$28.88B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
20.99
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
-1.75%
1M Leistung:
+1.38%
6M Leistung:
+14.06%
1J Leistung:
+49.28%
1-Tages-Spanne:
$194.04
$200.26
1-Wochen-Bereich:
$194.04
$203.45
52-Wochen-Spanne:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, NVS, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
195.61 | 29.33B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,122.50 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
235.18 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
222.47 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.93 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.17 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story - simplywall.st
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Biogen Inc. (BIIB) Stock Analysis: Navigating a 10% Upside Potential with Strategic Collaborations - DirectorsTalk Interviews
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA) - The Globe and Mail
Biogen Inc. Stock (US09062X1037): Analyst Needham Sticks With Buy Rating - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages Biogen Inc. (BIIB) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
ICICI Prudential Asset Management Co Ltd Has $1.67 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
FMR LLC's Strategic Acquisition of Biogen Inc Shares - GuruFocus
Muscle-Relaxing Athletic Shots - Trend Hunter
Biogen Inc. (BIIB) Announces Results of 2026 Annual Meeting of S - GuruFocus
Biogen Inc. (BIIB) tops Q1 earnings and revenue estimates - MSN
Biogen (NASDAQ: BIIB) director granted 1,505-share equity compensation award - Stock Titan
Biogen (BIIB) director receives 1,505 restricted stock units in grant - Stock Titan
Biogen (NASDAQ: BIIB) grants director 1,505 RSUs vesting by 2026 - Stock Titan
Biogen (NASDAQ: BIIB) director Jesus B. Mantas awarded 1,505-share stock grant - Stock Titan
[Form 4] BIOGEN INC. Insider Trading Activity - Stock Titan
Biogen (NASDAQ: BIIB) awards 1,505 RSUs to company director - Stock Titan
Biogen (BIIB) director Menelas Pangalos receives stock grant and exercises 2,370 RSUs - Stock Titan
Biogen (BIIB) director Lloyd Minor receives 1,505-share equity award in Form 4 filing - Stock Titan
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Invest - GuruFocus
Biogen (NASDAQ: BIIB) director receives 2,005 restricted stock unit award - Stock Titan
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
City Therapeutics - The Pharma Letter
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Did FDA Breakthrough Status for Salanersen Just Shift Biogen's (BIIB) Long-Term SMA Strategy? - simplywall.st
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names - Insider Monkey
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen (NASDAQ: BIIB) posts 2026 director and proposal vote tallies - Stock Titan
Biogen (NASDAQ: BIIB) deems Apellis acquisition not significant - Stock Titan
Biogen Inc. stock (US09062X1037): Alzheimer’s setback, pipeline hopes and what’s next - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Stockholders to Connect - ACCESS Newswire
Biogen (NASDAQ:BIIB) Stock Acquired Rep. Maria Elvira Salazar - MarketBeat
Biogen (NASDAQ:BIIB) Shares Bought Rep. Maria Elvira Salazar - MarketBeat
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance
Biogen Stock (BIIB) Opinions on Congressional Purchases and Analyst Upgrade - Moomoo
Maria Elvira Salazar invests in Biogen, Datadog and IBM; sells Sherwin-Williams and Whirlpool stocks By Investing.com - Investing.com Nigeria
Is Biogen Inc (BIIB) Overvalued After 3.4% Rally? GF Value Says - GuruFocus
This House of Representative Just Bought Up To $375K In Biogen Stock - Benzinga
Biogen Inc Annual Shareholders Meeting Transcript - GuruFocus
Alzheimer's Therapeutics Market Dominated by North America, Biogen and Eli Lilly Drive Treatment Advances - openPR.com
Biogen To End Investors' Alzheimer's Drug Case For $18.9M - Law360
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Inc. (BIIB) Faces Securities Fraud Investigation After Cl - GuruFocus
Biogen (BIIB) Upgraded to Buy with Target Price of $255 - GuruFocus
Biogen's Base Is Declining — But 8 Pipeline Readouts Could Flip The Story - Benzinga
Biogen to pay $18.9 million to settle investors' claims over Alzheimer's drug - Reuters
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-06-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Stockholders to Learn More About the Investigation | NDAQ:BIIB | Press Release - Stockhouse
Biogen Inc. stock (US09062X1037): Alzheimer’s portfolio and pipeline in focus after recent updates - AD HOC NEWS
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Keeney Adam | Head of Corporate Development |
May 01 '26 |
Option Exercise |
0.00 |
939 |
0 |
6,820 |
| Godbout Sean | Chief Accounting Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
181 |
0 |
1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Viehbacher Christopher | President and CEO |
Feb 06 '26 |
Option Exercise |
0.00 |
24,461 |
0 |
36,548 |
| Singhal Priya | Head of Development |
Feb 06 '26 |
Option Exercise |
0.00 |
6,900 |
0 |
12,115 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 06 '26 |
Option Exercise |
0.00 |
8,725 |
0 |
21,016 |
| Kramer Robin | Chief Financial Officer |
Feb 06 '26 |
Option Exercise |
0.00 |
5,003 |
0 |
12,535 |
| Keeney Adam | Head of Corporate Development |
Feb 06 '26 |
Option Exercise |
0.00 |
5,080 |
0 |
6,875 |
| Izzar Rachid | Head of Global Product Strat. |
Feb 06 '26 |
Option Exercise |
0.00 |
6,889 |
0 |
11,786 |
0.15%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):